Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the offering of 4,375,000 shares of common stock, alongside an equal number of Class E and Class F Common Warrants to purchase additional shares. The offering also includes up to 4,375,000 Pre-Funded Warrants to purchase common stock, with the potential for up to 13,125,000 shares of common stock underlying the warrants. This best efforts public offering aims to raise capital for the continued clinical development of Panbela's lead drug candidates, ivospemin and Flynpovi, as well as for general corporate purposes. The offering is set to terminate on February 15, 2024, unless completed sooner or terminated at the company's discretion. Panbela's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced the offering of 4,375,000 shares of common stock, alongside an equal number of Class E and Class F Common Warrants to purchase additional shares. The offering also includes up to 4,375,000 Pre-Funded Warrants to purchase common stock, with the potential for up to 13,125,000 shares of common stock underlying the warrants. This best efforts public offering aims to raise capital for the continued clinical development of Panbela's lead drug candidates, ivospemin and Flynpovi, as well as for general corporate purposes. The offering is set to terminate on February 15, 2024, unless completed sooner or terminated at the company's discretion. Panbela's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
临床阶段的生物制药公司Panbela Therapeutics, Inc. 宣布发行4,375,000股普通股，以及同等数量的E类和F类普通认股权证，用于购买更多股份。此次发行还包括多达4,375,000份用于购买普通股的预先注资认股权证，认股权证基础可能有多达13,125,000股普通股。此次尽最大努力的公开募股旨在为Panbela的主要候选药物依沃司佩明和Flynpovi的持续临床开发以及一般公司用途筹集资金。除非提前完成或由公司自行决定终止，否则此次发行定于2024年2月15日终止。Panbela的普通股在纳斯达克资本市场上市，股票代码为 “PBLA”。
临床阶段的生物制药公司Panbela Therapeutics, Inc. 宣布发行4,375,000股普通股，以及同等数量的E类和F类普通认股权证，用于购买更多股份。此次发行还包括多达4,375,000份用于购买普通股的预先注资认股权证，认股权证基础可能有多达13,125,000股普通股。此次尽最大努力的公开募股旨在为Panbela的主要候选药物依沃司佩明和Flynpovi的持续临床开发以及一般公司用途筹集资金。除非提前完成或由公司自行决定终止，否则此次发行定于2024年2月15日终止。Panbela的普通股在纳斯达克资本市场上市，股票代码为 “PBLA”。
有用
没用